Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

Summary

This is a five-part study being conducted to evaluate the safety, tolerability and pharmacokinetics of the HU6 tablet and capsule formulations at steady state in the fed and fasted state for HU6 450 mg once daily (QD) dose (as single or multiple tablets) or HU6 300 mg twice daily (BID) (supplied as two 150 mg tablets) or HU6 150 mg drug substance in a capsule × 3 (450 mg total dose) QD or HU6 150 mg granulated blend in a capsule × 3 (450 mg total dose) QD.

Timeline

Start

2025-10-13

Primary completion

2025-12-04

Completion

2025-12-04

Drugs

Indications